The Role of the PBM and Express Scripts in Healthcare

Biosimilars represent largely one of the greatest affordability gains or improvements in affordability for the American public. 2023 is a big transitional year where new biosimilars will be available and signa through our Evanworth business portfolio and our Credo specialty pharmacy is a leader in the space. So we'll be able to bring more choice to our patients and customers, improve the affordability to our clients be there in employer or health plan and lower out-of-pocket costs for individuals. And that curve, Jim, that your referencing is just starting. 2023 will accelerate further in 2024 and 2025 with more choice being brought forward for beneficiaries and improved affordability. It's an exciting time and we're